2018 年美国四个州、印第安人医疗保健系统的丙型肝炎药物处方和医疗补助政策。
Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018.
机构信息
Northwest Portland Area Indian Health Board, 2121 Broadway Suite 300, Portland, OR, 97201, USA.
United States Indian Health Service, 5600 Fishers Lane, Rockville, MD, 20857, USA.
出版信息
Int J Equity Health. 2019 Dec 4;18(1):190. doi: 10.1186/s12939-019-1101-4.
Abstract
Medicaid, the state-level public insurance in the United States, has widely differing criteria treatment for hepatitis C virus (HCV) such as stage of liver fibrosis, documented sobriety, and specialist consultation. In a rural health network, facilities located in two less restrictive states prescribed HCV drugs at a significantly higher rate than two more restrictive states (rate ratio 4.7, CI 2.6-8.5). Prescription rates per population were highly associated with HCV treatment policies.
摘要
美国州级公共保险医疗补助对丙型肝炎病毒（HCV）的治疗标准存在很大差异，例如肝纤维化分期、有记录的戒酒情况和专家咨询。在一个农村医疗网络中，位于两个限制较少的州的医疗机构开处 HCV 药物的比率明显高于两个限制较多的州（比率比 4.7，95%置信区间 2.6-8.5）。每人口的处方率与 HCV 治疗政策密切相关。
相似文献
1
Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018.2018 年美国四个州、印第安人医疗保健系统的丙型肝炎药物处方和医疗补助政策。
Int J Equity Health. 2019 Dec 4;18(1):190. doi: 10.1186/s12939-019-1101-4.
2
Medicaid Expansion and Restriction Policies for Hepatitis C Treatment.医疗补助扩大和丙型肝炎治疗限制政策。
JAMA Netw Open. 2024 Jul 1;7(7):e2422406. doi: 10.1001/jamanetworkopen.2024.22406.
3
Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured.医疗补助丙型肝炎病毒治疗政策：对商业保险人群检测和治疗的影响。
Am J Prev Med. 2022 Sep;63(3):e87-e98. doi: 10.1016/j.amepre.2022.03.010. Epub 2022 Jun 18.
4
A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.印度卫生服务机构中与药剂师合作进行丙型肝炎病毒协同护理的区域分析。
J Prim Care Community Health. 2018 Jan-Dec;9:2150132718807520. doi: 10.1177/2150132718807520.
5
State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.2015 - 2016年美国注射吸毒者的丙型肝炎病毒（HCV）发病率及与HCV预防和治疗服务相关的政策
MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):465-469. doi: 10.15585/mmwr.mm6618a2.
6
Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.受控物质处方模式 - 处方行为监测系统，八个州，2013 年。
MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.
7
Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.宾夕法尼亚州医疗补助计划中丙型肝炎治疗预先授权标准的长期疾病和经济结果。
Healthc (Amst). 2017 Sep;5(3):105-111. doi: 10.1016/j.hjdsi.2016.11.001. Epub 2016 Dec 5.
8
Differences in the cost of antidepressants across state Medicaid programs.各州医疗补助计划中抗抑郁药物成本的差异。
J Ment Health Policy Econ. 2008 Mar;11(1):33-47.
9
Rate and predictors of treatment prescription for hepatitis C.丙型肝炎治疗处方的比率及预测因素。
Gut. 2007 Mar;56(3):385-9. doi: 10.1136/gut.2006.099150. Epub 2006 Sep 27.
10
Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies - United States, 2007-2014.美沙酮处方与过量用药及其与医疗补助优选药物清单政策的关联——美国，2007 - 2014年
MMWR Morb Mortal Wkly Rep. 2017 Mar 31;66(12):320-323. doi: 10.15585/mmwr.mm6612a2.
引用本文的文献
1
Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.2000-2019 年美国丙型肝炎相关住院治疗的时间趋势。
Clin Infect Dis. 2023 Dec 15;77(12):1668-1675. doi: 10.1093/cid/ciad425.
2
Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.医疗补助管理式医疗药品除外计划与丙型肝炎病毒处方使用的关联。
JAMA Health Forum. 2021 Aug 27;2(8):e212285. doi: 10.1001/jamahealthforum.2021.2285. eCollection 2021 Aug.
3
Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.基于订阅的医疗补助支付模式及其对获取丙型肝炎药物的影响。
JAMA Health Forum. 2021 Aug 27;2(8):e212291. doi: 10.1001/jamahealthforum.2021.2291. eCollection 2021 Aug.
4
A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.针对无家可归者的医疗保健机构中的丙型肝炎消除模型：一种新型的反思性实验室算法与公平性评估。
Int J Drug Policy. 2021 Oct;96:103359. doi: 10.1016/j.drugpo.2021.103359. Epub 2021 Jul 27.
本文引用的文献
1
Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005-2015.评估美国印第安人卫生服务机构服务的美国印第安人或阿拉斯加原住民人群中丙型肝炎病毒诊断率的差异，2005-2015 年。
J Community Health. 2018 Dec;43(6):1115-1118. doi: 10.1007/s10900-018-0528-7.
2
Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.直接作用抗病毒药物持续病毒学应答：对无晚期肝病患者死亡率的影响。
Hepatology. 2018 Sep;68(3):827-838. doi: 10.1002/hep.29811. Epub 2018 May 14.
3
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.2003 - 2013年美国丙型肝炎病毒相关死亡率上升
Clin Infect Dis. 2016 May 15;62(10):1287-1288. doi: 10.1093/cid/ciw111. Epub 2016 Mar 1.
4
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.简单、有效，但难以企及？丙型肝炎病毒药物对公共卫生的影响
N Engl J Med. 2015 Dec 31;373(27):2678-80. doi: 10.1056/NEJMe1513245. Epub 2015 Nov 17.
5
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.慢性丙型肝炎合并晚期肝纤维化患者持续病毒学应答与全因死亡率的关系。
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
Zotero 插件